The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 11,500.00
Ask: 12,200.00
Change: 0.00 (0.00%)
Spread: 700.00 (6.087%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: BAT On Fire After Half Year Earnings Surge

Thu, 26th Jul 2018 10:55

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------British American Tobacco, up 5.2%. The Dunhill, Kent and Lucky Strike cigarette maker said interim profit, revenue and cigarette volumes all grew strongly after its acquisition of Reynolds American and expects another "good" year of growth. For the six months ended June, pretax profit widened 31% to GBP3.97 billion from GBP3.03 billion the year prior. This was after revenue rose 57% to GBP11.64 billion from GBP7.42 billion the year before. Cigarette volumes jumped 10% to 345.0 billion sticks in the period. Performance was helped by its acquisition of Reynolds American Inc in July 2017. On a pro-forma basis - assuming BAT had owned Reynolds through the whole of 2017 - revenue rose 1.9% and cigarette volumes fell 3.1%.RELX, up 3.8%. The information and analytics group reported a flat performance in the first half of its current financial year, but said it is confident in delivering a year of earnings growth. The company said the six months to June 30 saw revenue down 1.4% to GBP3.65 billion, from GBP3.70 billion the year before, while adjusted profit before tax remained broadly flat at GBP1.05 billion. RELX declared an interim dividend increase of 6.0% to 12.40 pence from 11.70p paid for the same period a year earlier. The company said as it enters the second half of 2018, it is confident in delivering another year of underlying revenue, profit, and earnings growth.Smith & Nephew, up 3.7%. The medical devices maker reported a rise in interim revenue but a fall in profit, as it progressed a programme designed to generate annualised cost savings of USD50 million. Revenue for the first half of the year rose 4.3% to USD2.44 billion from USD2.34 billion, though pretax profit slipped 11% to USD341 million from USD383 million. The revenue growth included a foreign exchange tailwind of 3%, with sales up 1% on an underlying basis.AstraZeneca, up 2.8%. The Anglo-Swedish drugmaker reported a fall in interim revenue and profit, but held its annual guidance. Total revenue for the first half of the year fell 1% at actual exchange rates, down 5% at constant currencies, to USD10.33 billion. Product sales rose 2% at actual exchange rates to USD10.02 billion but externalisation revenue - which includes royalties and milestone payments - was down 53% to USD318 million. Astra kept its interim dividend flat at USD0.90 per share, reiterating its annual guidance.----------FTSE 100 - LOSERS----------SSE, down 5.5%. The utility stock went ex-dividend meaning new buyers no longer qualify for the latest payout.Schroders, down 3.7%. The asset manager lifted its interim dividend payout on the back of a rise in earnings and total assets under management. The company, however, added that no new business was generated by the asset management unit in the first half as inflows from institutional clients were offset by outflows in the intermediary sales channel. The wealth management unit recorded net inflows of GBP1.20 billion in the period, however. Total assets under management and administration as at June 30 totalled GBP449.4 billion, up from GBP447.0 billion as at December 31. GlaxoSmithKline, down 3.0%. The drugmaker said an advisory panel of US Food & Drug Administration has recommended against approval of mepolizumab for the treatment of chronic obstructive pulmonary disease, a type of lung condition that causes breathing difficulties. Glaxo said the Pulmonary Allergy Drugs Advisory Committee has voted that the risk-benefit profile was not adequate to support approval of mepolizumab as an add-on treatment for the reduction of exacerbations in patients with chronic obstructive pulmonary disease. Royal Dutch Shell 'B', down 2.5%, Shell 'A', down 2.5%. The oil major announced a share buyback worth USD25 billion, though the company missed expectations despite a sharp rise in earnings. Shell also lowered its production guidance for the third quarter in both its Upstream and Integrated Gas businesses, partly due to its current divestment programme. Shell launched a buyback of "at least" USD25 billion for the period 2018 to 2022. For the first tranche of this, Shell is to purchase shares up to USD2 billion of shares over a period of three months. Free cash flow for the quarter was USD9.53 billion, well below the USD12.16 billion a year prior, though up from the first quarter's USD5.18 billion. In the first half, free cash flow was USD14.71 billion, down from USD17.34 billion. Compass Group, down 2.3%. The contract caterer said it continues to trade well, though with margins slightly behind last year with a "challenging" cost and volume environment in the UK. In the company's financial third quarter, overall organic revenue grew 5.7% - up 5.1% excluding the impact of Easter, which fell in Compass's second quarter - driven by strong net new business in North America, an acceleration in Europe and good progress in Rest of World. ----------FTSE 250 - WINNERS----------Vesuvius, up 8.1%. The molten metal flow engineering firm reported a record trading profit as its end markets remained favourable in the first half, with the company now expecting to outperform consensus for the full-year. The group said revenue for the first half of 2018 rose 7.9% to GBP897.0 million from GBP831.5 million last year, as pretax profit soared 44% to GBP87.8 million from GBP60.8 million. Trading profit grew 15% to a "record" GBP99.6 million, as return on sales improved by 70 basis points to 11.1% from 10.4%.Renishaw, up 3.0%. The engineer hiked its annual payout following strong earnings growth across all of its geographies. The group reported a pretax profit of GBP155.2 million for the year to the end of June, up by a third from GBP117.1 million profit posted the year before. Revenue grew 14% to GBP611.5 million from GBP536.8 million. On a constant currency basis, it was 18% higher year-on-year. The company said revenue growth was boosted by a strong performance across all regions and divisions. Continental Europe came in as the best performer during the year with revenue up 19% to GBP154.2 million from GBP129.9 million.National Express, up 2.5%. The transport operator delivered its "best ever" half-year profit as it grew revenue in all divisions. For the six months to June 30, the company posted pretax profit of GBP80.1 million, improved to GBP64.6 million a year ago. Revenue rose 3.2% to GBP1.20 billion from GBP1.17 billion year-on-year, driven in particular by the growth in North America and in the company's Spanish division ALSA. All the company's divisions increased commercial passengers, with the group carrying nearly 1.5% more year-on-year, National Express said.----------FTSE 250 - LOSERS----------Cobham, down 10%. The defence and aerospace equipment supplier said it expects to take a GBP40 million hit related to its US KC-46 tanker programme, with Boeing Co currently withholding the payment of invoices. Cobham said while there has been progress on the programme, US aerospace firm Boeing has made "as yet unquantified damages assertions" relating to the programme. Consequently, Boeing is withholding payment of Cobham's KC-46 CDS and WARP invoices. Cobham said it is formally disputing Boeing's claims. Additionally, completion of CDS qualification has taken longer and been "more challenging" than expected.Intu Properties,down 6.5%. The shopping centre operator said net rental income and occupancy remained stable despite net asset value falling sharply in a weak UK retail environment. For the six months ended June, net asset value per share fell to 362 pence from 411p at the end of 2017. Net rental income also dropped modestly to GBP223.1 million from GBP226.2 million the year prior. Occupancy fell to 96.6% at the end of June, from 97.0% six months earlier and 96.8% the year prior. The proportion of tenants trading in administration, however, fell to 0.3% from 0.6% six months earlier. Intu proposed a flat interim dividend per share at 4.6p.Howden Joinery, down 5.3%. The kitchen supplier said new product initiatives and higher costs of goods dented first half profit growth. The company also said revenue for the core UK division in the first four weeks of second half to July 14 increased by 5.3% and overall expectations for the full year remain unchanged. For the 24 weeks to June 16, the company recorded pretax profit of GBP68.8 million, up from GBP65.6 million in the year ago period, on a revenue of GBP619.4 million and GBP553.0 million, respectively. The core UK unit delivered revenue of GBP604.7 million, up from GBP539.5 million a year ago. Gross profit margin fell to 61.3% from 64.1% due to sales initiatives and increases in costs of goods sold. The company expects inflationary pressures on the costs of goods sold to continue for the remaining part of 2018.----------
More News
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.